|
副產品高沸點芳烴溶劑的產銷量大幅下降；同時因裝置產能利用率偏低、同比下降20.09%；歸母淨利潤為987.51萬元，報告期內受原油價格波動影響，正丹股份4月15日晚披露的2023年度業績快報顯示，正丹股 |
光算蜘蛛池光算蜘蛛池光算谷歌外链光算爬虫池光算谷歌外鏈光算谷歌seo光算谷歌外鏈光算谷歌seo公司光算谷歌seo光算谷歌广告光算谷歌外鏈https://synapse.patsnap.com/article/what-is-the-mechanism-of-vistamrhttps://synapse.patsnap.com/article/avalo-q2-2024-financial-results-and-business-updateshttps://synapse.patsnap.com/article/jjprotagonists-icotrokinra-promising-in-phase-3-psoriasis-trialhttps://synapse.patsnap.com/article/fda-warns-of-rare-serious-liver-injury-with-veozah-for-menopausal-hot-flasheshttps://synapse.patsnap.com/article/what-is-carvedilol-phosphate-used-forhttps://synapse.patsnap.com/drug/af3e51ddfb2643a2889121cd2ca8ec06https://synapse.patsnap.com/article/what-are-the-side-effects-of-ozagrel-trometamolhttps://synapse.patsnap.com/article/what-is-brivudine-used-forhttps://synapse.patsnap.com/drug/d0f8e5664b3f451dac96eae7b6581899https://synapse.patsnap.com/drug/4a9d837755c6dd19a83cfcc250e12709https://synapse.patsnap.com/drug/9be0e98e9935480a9556241d697a92bdhttps://synapse.patsnap.com/article/targeting-and-clearance-of-al-amyloidosis-deposits-by-neod001-a-novel-therapeutic-approachhttps://synapse.patsnap.com/drug/d9dd5e11d2ad4d8b8e98596592b20966https://synapse.patsnap.com/drug/8bf658c729544ff492d4d88eecb4d9bfhttps://synapse.patsnap.com/drug/17b42021236b47d492334796fb0c0c7fhttps://synapse.patsnap.com/drug/c59ebefd99894f13a82dfc6ec8bda1b1https://synapse.patsnap.com/drug/2a9ecd08606e4ba0b03313d80c0e40dchttps://synapse.patsnap.com/drug/e6281d64c4a24b29a0ffccde9de908a6https://synapse.patsnap.com/article/what-are-the-side-effects-of-lonidaminehttps://synapse.patsnap.com/article/what-is-the-mechanism-of-pozelimabhttps://synapse.patsnap.com/drug/8d82046d5aae4190ad019ca258469350https://synapse.patsnap.com/article/what-are-hcv-e1-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/92b06ee525974c33ba5036f6444b9489https://synapse.patsnap.com/article/what-are-gfr%25CE%25B13-antagonists-and-how-do-they-workhttps://synapse.patsnap.com/drug/93b85b087e40434eb0de5c5c2a5bb0bdhttps://synapse.patsnap.com/article/what-are-the-primary-areas-of-focus-for-kezar-life-scienceshttps://synapse.patsnap.com/article/amicus-acquires-dimerix%25E2%2580%2599s-kidney-drug-for-30m-upfronthttps://synapse.patsnap.com/article/what-are-cacna1g-blockers-and-how-do-they-workhttps://synapse.patsnap.com/drug/f8ca4157e9e4470da1e1979255cb7308https://synapse.patsnap.com/article/mtti-reports-on-225ac-ebtate-and-177lu-ebtate-at-2024-snmmi-annual-meeting